0400
#2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FREDEKING *et al.*
Serial No.: 10/038,557
Filed: January 3, 2002

For: *COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS*

Art Unit: Unassigned
Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents
Washington, D.C. 20231, on this date.

02/20/02
Date

Lynn Morkunas

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Transmitted herewith are an Information Disclosure Statement and Forms PTO-1449 (40 Pages) for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

☒ The Commissioner is hereby authorized to charge any fee, including any submitted herewith if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By: _____
Stephanie Seidman
Registration No. 33,779

Attorney Docket No. 24881-301D
Address all correspondence to:
Stephanie Seidman, Esq.
HELLER EHRMAN WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
E-mail: sseidman@HEWM.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FREDEKING *et al.*
Serial No.: 10/038,557
Filed: January 3, 2002

For: *COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS*

Art Unit: Unassigned
Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents Washington, D.C. 20231, on this date.

02/20/02
Date

Lynn Morkunas

INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Since this Information Disclosure Statement is filed before the receipt of a first Office Action on the merits for the above-captioned application, no filing fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. The Forms PTO-1449 (40 pages) are provided herewith. In accordance with 37 C.F.R. §1.98(d), copies of the references marked with an asterisk are not provided herewith, as they have been previously provided in connection with application U.S. Serial Nos. 09/301,274 and 09/562,979, which are relied upon for an earlier filing date in accordance with 35 U.S.C. §120.

The documents listed on the Forms PTO-1449 are in the English language with the exception of items JP, QG, QI, QM, QP, RE, TD, TO, TP, US, WF, and WX. Item JP (Japanese Patent No. 0038841) is in the Japanese language and was supplied with an English language Derwent Abstract in the parent case. Items QG, QI, QM, QP, RE, TD, TO, TP, WF, and WX are in a foreign language and were supplied with English language abstracts in the parent case. Item US is in the Russian language and was supplied with a certified English language translation in the parent case. Hence, in accordance with the

requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following co-pending U.S. and International applications that have one or more common inventors and/or one or more common owners:

U.S.S.N.	Filing Date	Docket No.
09/301,274	04/27/99	301
09/562,979	04/27/00	301B
09/840,707	04/23/01	301C
Int'l App. No.	Filing Date	Docket No.
PCT/US00/11700	04/26/00	301PC

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,
HELLER EHRMAN WHITE & McAULIFFE LLP

By: _____
Stephanie Seidman
Registration No. 33,779

Attorney Docket No. 24881-301D
Address all correspondence to:
Stephanie Seidman, Esq.
HELLER EHRMAN WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, California 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
E-mail: sseidman@HEWM.com

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	SERIAL NO.
24881-301D	10/038,557
APPLICANT	
FREDEKING *et al.*	
FILING DATE	GROUP
January 3, 2002	1646

** Copies of articles not enclosed.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	AA			H	1	5	0	9	12/05/95	Eran *et al.*	530	383	06/04/93
*	AB	R	E	2	9	6	9	8	07/11/78	Fekete *et al.*	260	112 B	04/06/76
*	AC	R	E	3	4	6	5	6	07/05/94	Golub *et al.*	514	152	05/04/92
*	AD	R	E	3	5	4	5	0	02/11/97	Dower *et al.*	530	351	06/14/93
*	AE	2	4	8	2	0	5	5	09/13/49	Duggar *et al.*	167	65	02/11/4/
*	AF	2	5	1	6	0	8	0	07/18/50	Sobin *et al.*	167	65	11/28/49
*	AG	2	6	9	9	0	5	4	01/11/55	Conover	260	559	10/09/53
*	AH	2	7	1	2	5	1	7	07/05/55	Gourevitch *et al.*	195	114	03/03/54
*	AI	2	8	7	8	2	8	9	03/17/59	McCormick *et al.*	260	559	05/28/56
*	AJ	2	8	8	6	5	9	5	05/12/59	Heinemann *et al.*	260	559	09/30/58
*	AK	2	8	9	9	4	2	2	08/11/59	Winterbottom *et al.*	260	207	08/31/56
*	AL	2	9	8	7	4	4	9	06/06/61	Miller *et al.*	195	80	02/23/60
*	AM	3	0	0	5	0	2	3	10/17/61	Miller	260	559	04/05/57
*	AN	3	0	1	2	9	4	6	12/12/61	Szumski	195	80	11/16/60
*	AO	3	0	1	9	1	7	2	01/30/62	Goodman *et al.*	195	80	03/14/60
*	AP	3	0	1	9	1	7	3	01/30/62	Arishima *et al.*	195	80	06/04/56
*	AQ	3	0	2	6	3	5	4	03/20/62	Blackwood *et al.*	260	559	12/15/60
*	AR	3	0	5	0	4	4	6	08/21/62	Goodman *et al.*	195	80	07/28/60
*	AS	3	0	5	3	8	9	2	09/11/62	Sieger, Jr. *et al.*	260	559	04/27/60
*	AT	3	1	4	8	2	1	2	09/08/64	Boothe *et al.*	260	559	12/22/61
*	AU	3	1	5	4	4	7	6	10/27/64	Neidleman	195	80	04/29/63
*	AV	3	2	0	0	1	4	9	08/10/65	Blackwood *et al.*	260	559	05/05/61
*	AW	3	2	2	6	4	3	6	12/28/65	Petisi *et al.*	260	559	05/17/63

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	AX	3	3	0	1	8	9	9	01/31/67	Kaplan *et al.*	260	559	11/27/63
*	AY	3	4	6	4	8	9	0	09/02/69	Weichselbaum	196	66	03/01/65
*	AZ	3	5	3	6	8	0	9	10/27/70	Applezweig	424	28	02/17/69
*	BA	3	5	9	8	1	2	3	08/10/71	Zaffaroni	128	268	04/01/69
*	BB	3	6	3	0	2	0	0	12/28/71	Higuchi	128	260	06/09/69
*	BC	3	6	3	1	0	1	8	12/28/71	Shanbrom *et al.*	260	112	05/01/70
*	BD	3	6	4	7	0	7	0	03/07/72	Adler	210	83	06/11/70
*	BE	3	6	5	2	5	3	0	03/28/72	Johnson *et al.*	260	112	08/28/67
*	BF	3	6	8	2	8	8	1	08/08/72	Fekete *et al.*	260	112	06/19/69
*	BG	3	7	8	0	9	3	5	12/25/73	Lukacs *et al.*	233	1 A	06/10/72
*	BH	3	8	4	5	7	7	0	11/05/74	Theeuwes *et al.*	128	260	06/05/72
*	BI	3	8	4	7	7	7	0	11/12/74	Radlowe *et al.*	204	159.23	11/12/73
*	BJ	3	8	5	2	1	9	4	12/03/74	Zine, Jr.	210	83	12/11/72
*	BK	3	9	1	6	8	9	9	11/04/75	Theeuwes *et al.*	128	260	02/07/74
*	BL	3	9	3	2	4	9	0	01/13/76	Fernandez	260	501.11	12/04/72
*	BM	3	9	4	7	5	1	7	03/30/76	Muxfeldt *et al.*	260	559	12/29/72
*	BN	3	9	5	7	9	7	2	05/18/76	Weber *et al.*	424	80	06/28/72
*	BO	3	9	5	7	9	8	0	05/18/76	Noseworthy	424	227	06/10/74
*	BP	3	9	6	2	1	3	1	06/08/76	Faubl *et al.*	252	429 R	01/28/75
*	BQ	3	9	6	2	3	3	0	06/08/76	Cotti	260	559	09/24/74
*	BR	3	9	6	2	4	3	5	06/08/76	Grunberg *et al.*	424	227	12/09/74
*	BS	3	9	7	3	0	0	2	08/03/76	Hagan *et al.*	424	101	05/01/75
*	BT	3	9	8	3	1	7	3	09/28/76	Hartung *et al.*	260	559	10/31/74

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	SERIAL NO.
24881-301D	10/038,557
APPLICANT	
FREDEKING *et al.*	
FILING DATE	GROUP
January 3, 2002	1646

** Copies of articles not enclosed.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	BU	3	9	9	3	6	9	4	11/23/76	Martin *et al.*	260	559	04/11/75
*	BV	4	0	0	8	7	1	9	02/22/77	Theeuwes *et al.*	128	260	02/02/76
*	BW	4	0	1	8	8	8	9	04/19/77	Armstrong	424	80	01/02/76
*	BX	4	0	2	0	1	6	2	04/26/77	Ghilardi *et al.*	424	227	02/07/75
*	BY	4	0	2	5	5	0	0	05/24/77	Garcia *et al.*	260	112 B	11/21/75
*	BZ	4	0	6	0	6	0	5	11/29/77	Cotti	424	227	09/25/75
*	CA	4	0	6	1	6	7	6	12/06/77	Villax	260	559	03/23/76
*	CB	4	0	6	6	6	9	4	01/03/78	Blackwood *et al.*	260	559	01/22/73
*	CC	4	0	6	9	2	1	6	01/27/78	Shanbrom	260	112 B	01/30/76
*	CD	4	0	7	5	1	9	3	02/21/78	Campbell *et al.*	260	112 B	11/26/76
*	CE	4	0	8	1	5	2	7	03/28/78	Armstrong *et al.*	424	80	12/07/76
*	CF	4	0	8	1	5	2	8	03/28/78	Armstrong	424	80	12/07/76
*	CG	4	0	8	2	7	3	4	04/04/78	Stephan	260	112 B	05/19/76
*	CH	4	0	8	6	3	3	2	04/25/78	Armstrong	424	80	12/07/76
*	CI	4	0	8	9	9	4	4	05/16/78	Thomas	424	101	10/05/76
*	CJ	4	1	0	4	2	6	6	08/01/78	Wickerhauser	260	112 B	04/14/77
*	CK	4	1	2	4	5	7	6	11/07/78	Coval	260	112 B	12/03/76
*	CL	4	1	4	0	6	3	1	02/20/79	Okuda *et al.*	210	83	09/29/77
*	CM	4	1	5	4	8	1	9	05/15/79	Stephan	424	101	09/07/76
*	CN	4	1	6	4	4	9	6	08/14/79	Hao	260	122	08/23/78
*	CO	4	1	6	8	3	0	3	09/18/79	Nishida *et al.*	424	85	06/07/78
*	CP	4	1	7	0	6	3	9	10/09/79	Liu *et al.*	424	101	07/10/78
*	CQ	4	1	9	7	2	3	8	04/08/80	Murata *et al.*	260	122	08/22/78

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	SERIAL NO.
24881-301D	10/038,557
APPLICANT	
FREDEKING *et al.*	
FILING DATE	GROUP
January 3, 2002	1646

** Copies of articles not enclosed.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	CR	4	2	0	3	8	9	1	05/20/80	Rock	260	112 B	12/29/77
*	CS	4	2	1	0	5	8	0	07/01/80	Amrani	260	112 B	06/19/79
*	CT	4	2	2	2	9	3	4	09/16/80	Hao	260	122	04/12/79
*	CU	4	2	5	1	4	3	7	02/17/81	Rasmussen *et al.*	260	112 B	10/26/79
*	CV	4	2	5	9	3	3	1	03/31/81	Armstrong	424	227	04/16/79
*	CW	4	2	8	9	6	9	1	09/15/81	Rock *et al.*	260	112 B	11/26/80
*	CX	4	3	4	7	1	3	8	07/31/82	Ohno *et al.*	210	639	12/03/80
*	CY	4	3	4	8	3	1	5	09/07/82	Blomback *et al.*	260	112 B	12/11/80
*	CZ	4	3	7	4	7	6	3	02/22/83	Takagi	260	112 B	08/28/80
*	DA	4	3	7	6	1	1	8	03/08/83	Daher *et al.*	424	227	05/19/81
*	DB	4	3	8	3	9	8	9	05/17/83	Rock	124	101	11/02/81
*	DC	4	3	8	6	0	6	8	05/31/83	Mitra *et al.*	424	101	02/26/80
*	DD	4	3	8	6	0	8	3	05/31/83	Hacke *et al.*	424	227	09/17/81
*	DE	4	3	9	9	1	2	7	08/16/83	Hacke *et al.*	424	227	09/08/81
*	DF	4	4	0	4	1	3	1	09/13/83	Schwarz *et al.*	260	112 B	07/29/81
*	DG	4	4	1	8	0	6	0	11/29/83	Kahan nee Laszlo *et al.*	424	227	09/17/79
*	DH	4	4	3	5	3	1	8	03/06/84	Pabst *et al.*	260	112 B	05/22/81
*	DI	4	4	3	6	7	2	4	03/13/84	Ohnishi *et al.*	424	101	05/26/82
*	DJ	4	4	7	7	5	7	5	10/16/84	Vogel *et al.*	436	170	08/04/81
*	DK	4	5	2	2	7	5	1	06/11/85	Linnau *et al.*	260	112 B	05/18/84
*	DL	4	5	2	2	8	1	1	06/11/85	Eppstein *et al.*	514	2	07/08/82
*	DM	4	5	4	3	2	1	0	09/24/85	Mitra *et al.*	260	112 B	10/04/84
*	DN	4	5	8	4	1	3	5	04/22/86	Balint *et al.*	260	351.6	09/29/83

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
APPLICANT FREDEKING *et al.*	
FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	DO	4	6	6	6	8	9	7	05/19/87	Golub *et al.*	514	152	12/29/83
*	DP	4	6	8	7	6	1	0	08/18/87	Vassilatos	264	211.14	04/30/86
*	DQ	4	6	9	2	3	3	1	09/08/87	Uemura *et al.*	424	85	02/24/84
*	DR	4	7	0	1	3	2	0	10/20/87	Hasegawa *et al.*	424	54	11/26/85
*	DS	4	7	0	4	3	8	3	11/03/87	McNamara *et al.*	514	152	02/07/85
*	DT	4	7	4	3	6	8	0	05/10/88	Mathews *et al.*	530	383	02/01/85
*	DU	4	7	6	9	0	2	7	09/06/88	Baker *et al.*	424	493	02/24/87
*	DV	4	7	7	2	6	8	5	09/20/88	Schmidt *et al.*	530	326	11/02/85
*	DW	4	7	7	8	8	0	6	10/18/88	Bender *et al.*	514	336	08/19/86
*	DX	4	7	8	0	4	7	0	10/25/88	Bender *et al.*	514	341	08/19/86
*	DY	4	7	9	4	1	1	4	12/27/88	Bender *et al.*	514	333	06/17/87
*	DZ	4	8	0	3	1	5	3	02/07/89	Shibata *et al.*	435	2	03/18/86
*	EA	4	8	1	4	4	3	5	03/21/89	Schwarz *et al.*	530	383	10/15/87
*	EB	4	8	2	9	0	5	7	05/09/89	Brox *et al.*	514	152	05/13/88
*	EC	4	8	3	5	2	5	7	05/30/89	Friedrich-Fiechtl *et al.*	530	387	11/19/87
*	ED	4	8	3	7	0	3	0	06/06/89	Valorose, Jr. *et al.*	424	456	10/06/87
*	EE	4	8	6	1	7	9	4	08/29/89	Otterness	514	414	04/13/88
*	EF	4	8	7	0	1	0	1	09/26/89	Ku *et al.*	514	476	02/18/88
*	EG	4	9	2	5	8	3	3	05/15/90	McNamara *et al.*	514	152	12/29/86
*	EH	4	9	3	5	4	1	2	06/19/90	McNamara *et al.*	514	152	07/13/87
*	EI	4	9	3	5	4	2	2	06/19/90	Patil	514	237.5	12/15/88
*	EJ	4	9	5	2	6	7	5	08/28/90	Mathews *et al.*	530	383	12/29/88
*	EK	4	9	7	5	4	6	7	12/04/90	Ku *et al.*	514	712	03/26/90

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	EL	4	9	7	7	2	4	6	12/11/90	Lee *et al.*	530	383	06/06/89
*	EM	4	9	9	4	5	5	3	02/19/91	Schmidt *et al.*	530	327	06/17/88
*	EN	5	0	1	1	8	5	7	04/30/91	Ku *et al.*	514	653	07/28/89
*	EO	5	0	2	1	4	0	7	06/04/91	Levy	514	154	04/11/86
*	EP	5	0	2	8	4	2	0	07/02/91	Masegi *et al.*	424	85.1	07/26/88
*	EQ	5	0	3	4	4	1	2	07/23/91	Ku *et al.*	514	529	12/19/90
*	ER	5	0	3	9	6	9	5	08/13/91	Parker *et al.*	514	422	02/27/90
*	ES	5	0	4	1	5	5	4	08/20/91	Parker *et al.*	548	532	02/23/90
*	ET	5	0	5	9	5	9	5	10/22/91	Le Grazie	424	468	03/20/90
*	EU	5	0	7	1	8	5	2	12/10/91	Walker	514	272	12/01/89
*	EV	5	0	7	3	5	4	3	12/17/91	Marshall *et al.*	514	21	07/21/88
*	EW	5	0	7	5	2	2	2	12/24/91	Hannum *et al.*	435	69.1	04/06/90
*	EX	5	0	7	5	2	9	5	12/24/91	Zupan *et al.*	514	153	12/12/89
*	EY	5	1	1	8	5	0	0	06/02/92	Hanel *et al.*	424	85.1	05/25/89
*	EZ	5	1	2	0	5	4	8	06/09/92	McClelland *et al.*	424	473	11/07/89
*	FA	5	1	3	6	0	2	1	08/04/92	Dembinski *et al.*	530	350	02/27/90
*	FB	5	1	8	0	8	1	2	01/19/93	Dower *et al.*	530	351	12/21/89
*	FC	5	1	8	3	6	5	8	02/02/93	Lee *et al.*	424	89	11/16/89
*	FD	5	1	9	2	7	9	0	03/09/93	Goddard *et al.*	514	414	12/17/91
*	FE	5	2	1	5	8	9	9	06/01/93	Dattagupta	435	6	08/23/90
*	FF	5	2	2	3	2	4	8	06/29/93	McNamara *et al.*	424	49	02/11/91
*	FG	5	2	3	1	0	2	4	07/27/93	Moeller *et al.*	435	240.27	09/08/87
*	FH	5	2	4	7	0	7	0	09/21/93	Yamada *et al.*	530	351	09/20/91

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	SERIAL NO.
24881-301D	10/038,557
APPLICANT	
FREDEKING *et al.*	
FILING DATE	GROUP
January 3, 2002	1646

** Copies of articles not enclosed.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	FI	5	2	5	0	4	4	2	10/05/93	Cabezas	436	509	04/08/93
*	FJ	5	2	5	8	3	7	2	11/02/93	Levy	514	154	03/20/91
*	FK	5	2	6	2	1	7	3	11/16/93	Sheth *et al.*	424	494	03/02/92
*	FL	5	2	7	7	8	1	8	01/11/94	Matsuoka *et al.*	210	635	04/22/93
*	FM	5	2	7	7	9	1	6	01/11/94	Dwyer *et al.*	424	494	05/14/90
*	FN	5	2	8	6	8	4	7	02/15/94	Gehrke *et al.*	530	351	05/19/92
*	FO	5	2	9	8	4	2	3	03/29/94	Dalrymple *et al.*	435	320.1	11/14/91
*	FP	5	3	0	0	3	0	4	04/05/94	Sheth *et al.*	424	490	05/27/92
*	FQ	5	3	0	4	6	3	4	04/19/94	Schade	530	350	10/09/91
*	FR	5	3	0	6	7	3	2	04/26/94	Norris *et al.*	514	729	11/22/90
*	FS	5	3	0	8	8	3	9	05/03/94	Golub *et al.*	514	152	09/04/92
*	FT	5	3	1	0	8	7	7	05/10/94	Spencer	530	364	04/08/93
*	FU	5	3	1	9	0	7	1	06/07/94	Dower *et al.*	530	350	01/14/92
*	FV	5	3	2	1	0	1	7	06/14/94	Golub *et al.*	514	152	08/12/91
*	FW	5	3	3	4	3	8	0	08/02/94	Kilbourn *et al.*	424	85.2	06/30/92
*	FX	5	3	4	8	7	4	8	09/20/94	Sheth *et al.*	424	494	06/23/93
*	FY	5	3	5	0	6	8	3	09/27/94	Sims *et al.*	435	69.1	07/12/93
*	FZ	5	3	5	4	5	6	6	10/11/94	Addesso *et al.*	426	9	06/02/93
*	GA	5	3	5	9	0	3	9	10/25/94	Smith *et al.*	530	350	07/09/93
*	GB	5	3	6	0	7	1	6	11/01/94	Ohmoto *et al.*	435	7.2	02/16/93
*	GC	5	3	6	4	5	3	3	11/15/94	Ogura *et al.*	210	645	07/14/92
*	GD	5	3	8	7	7	0	3	02/07/95	Cakara *et al.*	552	203	10/20/93
*	GE	5	4	1	1	9	8	5	05/02/95	Bills *et al.*	514	460	05/17/93

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	SERIAL NO.
24881-301D	10/038,557
APPLICANT	
FREDEKING *et al.*	
FILING DATE	GROUP
January 3, 2002	1646

** Copies of articles not enclosed.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	GF	5	4	1	3	7	7	7	05/09/95	Sheth *et al.*	424	490	07/14/93
*	GG	5	4	2	0	1	5	4	05/30/95	Christensen, IV *et al.*	514	424	07/29/91
*	GH	5	4	2	2	1	0	4	06/06/95	Fiers *et al.*	424	85.1	11/20/91
*	GI	5	4	3	6	1	5	4	07/25/95	Barbanti *et al.*	435	240.27	12/13/91
*	GJ	5	4	5	3	4	9	0	09/26/95	Hageman *et al.*	530	350	08/30/94
*	GK	5	4	5	5	3	3	0	10/03/95	Haskill *et al.*	530	350	06/30/93
*	GL	5	4	6	4	9	3	7	11/07/95	Sims *et al.*	530	350	05/13/94
*	GM	5	4	6	4	9	3	8	11/07/95	Smith *et al.*	530	350	08/18/94
*	GN	5	4	7	8	9	2	5	12/26/95	Wallach *et al.*	530	351	08/07/92
*	GO	5	4	8	4	8	9	0	01/16/96	Johnson *et al.*	530	383	10/15/93
*	GP	5	4	8	6	4	6	3	01/23/96	Lesslauer *et al.*	435	69.5	01/01/93
*	GQ	5	4	8	8	0	3	2	01/30/96	Dower *et al.*	514	2	06/17/92
*	GR	5	4	9	2	8	8	8	02/20/96	Dower *et al.*	514	2	06/17/92
*	GS	5	4	9	4	6	7	1	02/27/96	Lai *et al.*	424	218.1	08/20/91
*	GT	5	5	0	8	2	6	2	04/16/96	Norman, Jr.	514	8	12/15/93
*	GU	5	5	1	9	0	0	0	05/21/96	Heavner *et al.*	514	12	04/01/94
*	GV	5	5	1	9	1	1	9	05/21/96	Yamada *et al.*	530	351	12/21/92
*	GW	5	5	2	3	2	9	7	06/04/96	Pruzanski *et al.*	514	152	04/21/95
*	GX	5	5	3	2	2	2	7	07/02/96	Golub *et al.*	514	152	12/21/94
*	GY	5	5	3	8	9	5	4	07/23/96	Koch *et al.*	514	53	06/24/94
*	GZ	5	5	4	1	2	1	9	07/30/96	Fenton *et al.*	514	432	03/04/93
*	HA	5	5	4	7	9	7	0	08/20/96	Weithmann *et al.*	514	378	03/28/95
*	HB	5	5	4	7	9	7	9	08/20/96	Christensen, IV *et al.*	514	424	04/19/95

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	HC	5	5	5	2	5	3	6	09/03/96	Nicholson *et al.*	536	23.1	04/08/94
*	HD	5	5	6	3	1	4	3	10/08/96	Cohan *et al.*	514	256	09/21/94
*	HE	5	5	8	2	9	9	8	12/10/96	Adolf	435	7.1	12/28/94
*	HF	5	5	9	1	7	6	7	01/07/97	Mohr *et al.*	514	413	06/06/95
*	HG	5	5	9	7	8	9	9	01/28/97	Banner *et al.*	530	351	03/24/94
*	HH	5	6	0	5	9	2	3	02/25/97	Christensen, IV *et al.*	514	417	03/05/93
*	HI	5	6	0	6	0	2	3	02/25/97	Chen *et al.*	530	351	05/24/94
*	HJ	5	6	1	6	4	9	0	04/01/97	Sullivan *et al.*	435	366	05/04/95
*	HK	5	6	2	6	3	2	1	05/06/97	Ulshafer, Jr.	248	231.41	02/27/95
*	HL	5	6	2	9	2	8	5	05/13/97	Black *et al.*	514	2	05/22/96
*	HM	5	6	3	9	4	7	6	06/17/97	Oshlack *et al.*	424	468	06/02/95
*	HN	5	6	4	1	7	5	1	06/24/97	Heavner	514	13	05/01/95
*	HO	5	6	4	6	1	5	4	07/08/97	Irie *et al.*	514	260	10/07/93
*	HP	5	6	4	8	3	5	9	07/15/97	Ohashi *et al.*	514	279	12/28/94
*	HQ	5	6	5	4	4	0	7	08/05/97	Boyle *et al.*	530	388.15	05/05/95
*	HR	5	6	5	6	2	7	2	08/12/97	Le *et al.*	424	133.1	02/04/94
*	HS	5	6	5	8	5	8	1	08/19/97	De Lacharriere *et al.*	424	401	12/28/95
*	HT	5	6	5	8	9	4	9	08/19/97	Aggarwal	514	557	11/30/94
*	HU	5	6	6	8	1	2	2	09/16/97	Fife *et al.*	514	152	05/01/95
*	HV	5	6	7	2	3	4	7	09/30/97	Aggarwal *et al.*	424	139.1	05/05/95
*	HW	5	6	7	4	5	3	3	10/07/97	Santus *et al.*	424	493	05/26/95
*	HX	5	6	9	1	3	8	2	11/25/97	Crimmin *et al.*	514	575	11/12/93
*	HY	5	6	9	5	9	5	3	12/09/97	Wallach *et al.*	435	69.1	04/30/92

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	SERIAL NO.
24881-301D	10/038,557
APPLICANT	
FREDEKING *et al.*	
FILING DATE	GROUP
January 3, 2002	1646

** Copies of articles not enclosed.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	HZ	5	6	9	8	1	9	5	12/16/97	Le *et al.*	424	133.1	10/18/94
*	IA	5	7	0	3	0	9	2	12/30/97	Xue *et al.*	514	303	04/16/96
*	IB	5	7	0	5	3	8	9	01/06/98	Braham *et al.*	435	375	11/18/94
*	IC	5	7	1	2	3	8	1	01/27/98	Lin *et al.*	536	23.5	08/15/96
*	ID	5	7	3	3	5	6	6	03/31/98	Lewis	424	426	10/30/95
*	IE	5	7	3	9	2	8	2	04/14/98	Colotta *et al.*	530	350	06/07/95
*	IF	5	7	4	1	4	8	8	04/21/98	Feldman *et al.*	424	154.1	10/06/93
*	IG	5	7	4	4	4	5	1	04/28/98	Allen *et al.*	514	18	08/13/96
*	IH	5	7	5	0	5	0	3	05/12/98	Alber *et al.*	514	12	05/05/95
*	II	5	7	5	3	6	2	8	05/19/98	Heavner *et al.*	514	17	06/07/95
*	IJ	5	7	6	3	4	4	6	06/09/98	Sadun *et al.*	514	263	03/26/92
*	IK	5	7	6	7	0	6	4	06/16/98	Sims *et al.*	514	2	05/16/95
*	IL	5	7	7	0	5	8	8	06/23/98	McNamara *et al.*	514	152	01/23/96
*	IM	5	7	7	3	4	3	0	06/30/98	Simon *et al.*	514	152	03/13/97
*	IN	5	7	7	3	5	8	2	06/30/98	Shin *et al.*	530	351	10/04/95
*	IO	5	7	7	6	8	9	5	07/07/98	Alber *et al.*	514	12	01/23/95
*	IP	5	7	7	6	9	4	7	07/07/98	Kroemer *et al.*	514	312	06/10/94
*	IQ	5	7	8	6	3	4	2	07/28/98	Carpenter *et al.*	514	54	06/05/95
*	IR	5	7	8	9	3	9	5	08/04/98	Amin *et al.*	514	152	08/30/96
*	IS	5	7	9	5	9	6	7	08/18/98	Aggarwal *et al.*	530	388.23	06/07/95
*	IT	5	8	0	4	5	9	9	09/08/98	Tanaka *et al.*	514	475	09/27/95
*	IU	5	8	0	8	0	2	9	09/15/98	Brockhaus *et al.*	536	23.5	05/19/95
*	IV	5	8	1	1	2	6	1	09/22/98	Wallach *et al.*	435	69.1	09/24/93

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	IW	5	8	1	7	4	7	6	10/06/98	Lin *et al.*	435	69.1	06/07/95
*	IX	5	8	2	7	8	4	0	10/27/98	Ramamurthy *et al.*	514	152	08/01/96
*	IY	5	8	3	7	4	9	5	11/17/98	Colotta *et al.*	435	69.1	08/13/97
*	IZ	5	8	4	3	6	7	5	12/01/98	Lin *et al.*	435	7.1	02/15/96
*	JA	5	8	4	3	9	0	4	12/01/98	Bemis *et al.*	514	18	12/20/95
*	JB	5	8	4	7	0	9	9	12/08/98	Lin *et al.*	536	23.5	05/17/96
*	JC	5	8	4	9	5	0	1	12/15/98	Lin *et al.*	435	7.1	06/19/95
*	JD	5	8	5	1	5	5	6	12/22/98	Breton *et al.*	424	639	04/10/96
*	JE	5	8	5	2	1	7	3	12/22/98	Lin *et al.*	530	350	09/26/95
*	JF	5	8	6	1	5	1	0	01/19/99	Piscopio *et al.*	544	131	04/20/95
*	JG	5	8	6	3	7	6	9	01/26/99	Young	435	69.52	01/28/97
*	JH	5	8	6	3	7	8	6	01/26/99	Feldmann *et al.*	435	252.3	06/06/95
*	JI	5	8	6	9	5	1	1	02/09/99	Cohan *et al.*	514	378	02/03/95
*	JJ	5	8	7	2	1	4	6	02/16/99	Baxter *et al.*	514	417	04/04/97
*	JK	5	8	7	7	1	5	1	03/02/99	Pereira	514	12	04/21/97
*	JL	5	8	8	6	0	1	0	03/23/99	Mori *et al.*	514	312	12/18/95
*	JM	6	0	2	0	4	7	7	02/01/00	Diu *et al.*	536	23.5	08/01/95
*	JN	6	0	7	1	5	1	4	06/06/00	Grinnell *et al.*	424	94.64	06/03/98
*	JO	6	0	7	1	5	1	6	06/06/00	Gonzalez *et al.*	424	130.1	04/01/99

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	Translation No
*	**JP**	0	0	3	8	8	4	1	06/07/73	JP			X	
*	JQ	1	3	4	4	6	4	5	10/21/63	FR			X	

EXAMINER | DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes	Translation No
*	JR	9	8	2	3	2	8	4	06/04/98	PCT				
*	JS	9	9	5	8	1	3	1	11/18/99	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	JT	Progress with Multiple Sclerosis: Control through inhibition of TNF-alpha production, *Cytokine Bulletin* Fall, 1995. http://www/rndsystems.com/asp/b_index.asp?ArticleID=85 (8/4/00)
*	JU	The Immune System And Parkinson's Disease: Focus on Inflammatory Cytokines, *Parkinson's Disease UPDATE Newsletter, Reprint from UPDATE Newsletter, Issue #54, 1995* Medicinal Publishing Company, Philadelphia, PA. http://www/chronicillnet.org/news/PD_update.html (2/19/01)
*	JV	Aderka et al., Stabilization of the Bioactivity of Tumor Necrosis Factor by Its Soluble Receptors, *J. Exp. Med.*, 175:323-9 (1992)
*	JW	Aderka et al., Variation in serum levels of the soluble TNF receptors among healthy individuals, *Lymphokine and Cytokine Res.*, 11(3):157-EOA (1992)
*	JX	Alford et al., Comparison of the inflammatory responses of mice infected with American and Australian *Trichinella pseudospiralis* or *Trichinella spiralis*, 28:343-8 (1998)
*	JY	Andus et al., High Concentations of Soluble Tumor Necrosis Factor Receptors in Ascites *Hepatol.*, 16(3):749-55 (1992)
*	JZ	Antin et al., Recombinant Human Interleukin-1 Receptor Antagonist in the Treatment of Steroid-Resistant Graft-Versus-Host Disease, *Blood*, 84(4):1342-1348 (1994)
*	KA	Appendix. Mediators of endothelial damage in sepsis, *Ann. Intern. Med.*, 115:464-466 (1991)
*	KB	Arend *et al.*, Interleukin-1 receptor antagonist, *Adv. Immunol.*, 54:167 (1993)
*	KC	Arend *et al.*, Biological Properties of Recombinant Human Monocyte-derived Interleukin 1 Receptor Antagonist, *J. Clin. Invest.*, 85:1694-1797 (1990)
*	KD	Asada, et al., Role of T Lymphocyte Subsets in Protection and Recovery from Hantaan Virus Infection in Mice, *J. Gen. Virol.*, 68(7):1961-9 (1987)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	KE	Attatippaholkun, et al., Nucleotide sequence and deduced amino acid sequence of the nonstructural proteins of Dengue type 3 virus, Bangkok genotype, *Southeast Asian J. Trop. Med. Public Health*, 29(2):361-6 (1998)
*	KF	Auperin, et al., Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and portection of guinea pigs froma lethal Lassa virus infection, *Virus Res.*, 9(2-3):233-48 (1988)
*	KG	Auperin, et al., Nucleotide sequence of the Lassa virus (Josiah Strain) S genome RNA and amino acid sequence comparison of the N and GPC proteins to other arenaviruses, *Virol.*, 168(2):421-5 (1989)
*	KH	Austgulen et al., Soluble TNF Receptors in Amniotic Fluid and in Urine from Pregnant Women, *J. Reproductive Immunol.*, 22:105-16 (1992)
*	KI	Avila, et al., Protection of Junin Virus-Infected Marmosets by Passive Administration of Immune Serum: Association With Late Neurologic Signs, *J. Med. Virol.*, 21(1):67-74 (1987)
*	KJ	Avirutnan et al., Dengue Virus Infection of Human Endothelial Cells Leads to Chemokine Production, Complement Activation, and Apoptosis, *J. Immunol.*, 161:6338-6346 (1998)
*	KK	Avsic-Zupanc, et al., Isolation of a strain of a Hantaan virus from a fatal case of hemorrhagic fever with renal syndrome in Slovenia, *Am. J. Trop. Med. Hyg.*, 51(4):393-400 (1994)
*	KL	Baize et al., Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients, *Nature Med.*, 5(4):423-426 (1999)
*	KM	Barandun, et al., Clinical tolerance and catabolism of plasmin-treated γ-glubulin for intravenous application, Vox Sang., 28:157-175 (1975)
*	KN	Barandun, et al., Intravenous administration of human γ-globulin, *Vox Sang.*, 7:157-174 (1962)
*	KO	Barardi, et al., Partial sequence analysis of type 1 Dengue virus coding for the nonstructural hydrophilic proteim NS-3, *Braz. J. Med. Biol. Res.*, 24(6):559-62 (1991)
*	KP	Barth, et al., Replication of dengue virus type 2, Brazilian strain, in mosquito cell cultures, *Mem. Inst. Oswaldo. Cruz.*, 86(1):123-4 (1991)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	KQ	Becker, Dangue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8+ cytotoxic T cells (CTLs)--a novel approach to the protection of humans, *Virus Genes*, 9(1):33-45 (1994)
*	KR	Beer et al., Characteristics of Filoviridae: Marburg and Ebola viruses, *Naturwissenschaften*, 86:8-17 Springer-Verlag (1999)
*	KS	Bendele et al., Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: Possible clinical implications, *J. Lab. Clin. Med.*, 125(4): 493-500 (1995)
*	KT	Bendele et al., Efficacy of Sustained Blood Levels of Interleukin-1 Receptor Antagonist in Animal Modesl of Arthritis, *Arthritis Rheum.*, 42(3):498-506 (1999)
*	KU	Benjamin et al., Hematopoietic activities of interleukin-1 alpha: in vitro and in vivo modulation by an anti-IL-1 receptor antibody, *Prog. Clin. Biol. Res.*, 349:355-63 (1990)
*	KV	Bernardi *et al.*, Tetracycline derivatives, *Farmaco Ed. Sci.*, 30:736 (1975)
*	KW	Beutler et al., Tumor necrosis, cachexia, shock, and inflammation: a common mediator, *Ann. Rev. Biochem.*, 57:505-18 (1988)
*	KX	Bhoopat, et al., Immunohistochemical characterization of a new monoclonal antibody reactive with dengue virus-infected cells in frozen tissue using immunoperoxidase technique, *Asian Pac. J. Allergy Immunol.*, 14(2):107-13 (1996)
*	KY	Biedrzycka, et al., Characterization of Protease Cleavage Sites Involved in the Formation of the Envelope Glycoprotein and Three Non-structural Proteins of Dengue Virus Type 2, New Guinea C Strain, *J. Gen. Virol.*, 68(5):1317-26 (1987)
*	KZ	Blackwood *et al.*, 6-Methylenetetracyclines. I. A new class of tetracycline antibiotics, *J. Am. Chem. Soc.*, 83:2773 (1961)
*	LA	Blackwood *et al.*, 6-Methylenetetracyclines III. Preparation and properties, *J. Am. Chem. Soc.*, 85:3943 (1963)
*	LB	Blejer, et al., Modelo rata-virus Junin: indicador de virulencia, *Medicina (B-Aires)*, 43(6pt2):898 (1983)
*	LC	Blejer, et al., Protection Conferred against Junin Virus Infectin in Rats, *Intervirol.*, 21(3):174-7 (1984)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	LD	Blok, et al., Comparison of a dengue-2 virus and its candidate vaccine derivative: sequence relationships with the flaviviruses and other viruses, *Virol.*, 187(2):573-90 (1992)
*	LE	Boothe et al., Tetracycline, *J. Am. Chem. Soc.*, 75:4621 (1953)
*	LF	Boothe et al., Total synthesis of tetracyclines. I. (+/-)-dedimethylamino-12 a-deoxy-6-demethylanhydrochlorotetracycline, *J. Am. Chem. Soc.*, 81:1006 (1959)
*	LG	Boxaca et al., Modification of Junin virus neutropism in the guinea pig model, *Acta Virol.*, 28(3):198-203 (1984)
*	LH	Boxaca, et al., Proteccion inducida en cobayo por la variante XJ del virus Junin, *Medicina (B Aires).*, 41(4):25-34 (1981)
*	LI	Breedveld et al., Minocycline Treatment for Rheumatoid Arthritis, *J. Rheumatol.* 17:43-46 (1990)
*	LJ	Brockmann, H. and B. Franck, Abbau der Actinomycine zu Desamino-actinomycinen, *Die Naturwissenschaften (Naturwiss)*, 41:451 (1954)
*	LK	Brockmann et al., Goemycin, *C.A.*, 53:4662h (1959)
*	LL	Broschard et al., Aureomycin, a new antibiotic, *Science*, 109:199 (1949)
*	LM	Burch et al., Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice, *J. Clin. Invest.*, 88(4):1190-6 (1991)
*	LN	Brown et al., Abstract: Antibiotic Therapy of rheumatoid Arthritis: An Observational Cohort Study of 98 Patients with 451 Patient-years of Follow-up (1985)
*	LO	Burkhardt, V.U. and H.J. Eggers, Viral infections-clinical and laboratory diagnosis. APrt 3: Hantaan virus and Hantaan-related viruses, hepatitis A and B, *Forschritte der Medizin* 111(33):528-9 (1993)
*	LP	Butcher et al., Comparison of two promotors controlling expression of secreted or intracellular IL-1 receptor antagonist[1], *J. Immunol.*, 153:701 (1994)
*	LQ	Cahour et al., Cleavage of the Dengue Virus Polyprotein at the NS3/NS4A and NS4B/NS5 Junctions Is Mediated by Viral Protease NS2B-NS3, Whereas NS4A/NS4B May Be Processed by a Cellular Protease, *J. Virol.*, 1992, 66:1535-42

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	LR	Cain et al., A cleavage-site-directed inhibitor of interleukin-1β-converting enzyme-like proteases inhibits apoptosis in primary cultures of rat hepatocytes, *J. Biochem.*, 314(Pt 1):27-32 (1996)
*	LS	Calandra et al., Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-1, Interferon-α, and Interferon-λ in the Serum of Patients with Septic Shock, *J. Infect. Dis.*, 161:982-987 (1990)
*	LT	Campetella et al., Susceptible adult murine model for Junin virus, *J. Med. Virol.*, 26(4):443-51 (1988)
*	LU	Cannon et al., Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever, *J. Infect. Dis.*, 161:79-84 (1990)
*	LV	Cardosa et al., A dot enzyme immunoassay for dengue 3 virus: comparison with the haemagglutination inhibition test, *Southeast Asian, J. Trop. Med. Public Health*, 19:591-4 (1988)
*	LW	Cardosa et al., *Clin. Diagn. Virol.*, 3:343-50 (1995)
*	LX	Cardosa et al., Development of a dot enzyme immunoassay for dengue 3: a sensitive method for the detection of antdengue antibodies, *J. Virol. Methods*, 22:81-8 (1988)
*	LY	Cargile et al., Effect of treatment with a monoclonal antibody against equine tumor necrosis factor (TNF) on clinical, hematologic, and circulating TNF responses of Miniature Horses given endotoxin, *Am. J. Vet. Res.*, 56(11):1451-9 (1995)
*	LZ	Celerier et al., In vitro modulation of epidermal inflammatory cytokines (IL-1α, IL-6, TNFα) by minocycline, *Arch. Dermatol. Res.*, 288:411-414 (1996)
*	MA	Chambers et al., Yellow fever virus proteins NS2A, NS2B, and NS4B: identification and partial N-terminal amino acid sequence analysis, *Virol.*, 169:100-9 (1989)
*	MB	Chan et al., The influence of antibody levels in dengue diagnosis by polymerase chain reaction, *J. Virol. Methods*, 49:315-22 (1994)
*	MC	Chen, et al., Nucleotide sequence of the envelope glycoprotein gene of a dengue-2 virus isolated during an epidemic of benign dengue fever in Tonga in 1974, *Nucl. Acids Res.*, 18(19):5889 (1990)
*	MD	Chen et al., Effects of interleukin-1α, Interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines, *Cancer Res.*, 58(16):3668-76 (1998)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	ME	Chouaib et al., More insights into the complex physiology of TNF, *Immunol.*, 12:141 (1991)
*	MF	Chow et al., Sequence analyses of NS3 genes of recent Pakistan and Singapore strains of dengue virus types 1 and 2, *Res Virol.*, 148(1):17-20 (1997)
*	MG	Chow, VTK., Molecular Diagnosis and Epidemiology of Dengue Virus Infection, *Ann. Acad. Med. Singapore*, 26:820-6 (1997)
*	MH	Chu, et al., A Vaccinia Virus-Vectored Hantaan Virus Vaccine Protects Hamsters from Challenge with Hantaan and Seoul Viruses but Not Puumala Virus, *J. Virol.*, 69(10):6417-23 (1995)
*	MI	Chupurnov, et al., *Vopr. Virusol.*, 40(6):257-60 (1995)
*	MJ	Church et al., Synthesis of 7-dimethylamino-6-demethyl-6-deoxytetracycline (Minocycline) *via* 9-nitro-6-demethyl-6-deoxytetracycline, *J. Org. Chem.*, 36:723 (1971)
*	MK	Clark et al., An antibody to a 17 amino acid synthetic peptide of the type 1 interleukin-1 receptor preferentially blocks interleukin-1β binding, *J. Interferon Cytokine Res.*, 16(12):1079-88 (1996)
*	ML	Clegg, et al., Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products, *Virus Res.*, 18(2-3):151-64 (1991)
*	MM	Cohn et al., Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids, *J. Am. Chem. Soc.*, 68:459-475 (1946)
*	MN	Colagiovanni et al., Evaluation of interleukin-1 receptor antagonist (IL-1RA) and tumor necrosis factor binding protein (TNF-BP) in a rodent abscess model of host resistance, *Immunopharmacol. Immunotoxicol.*, 18(3):397-419 (1996)
*	MO	Cominelli et al., Rabbit interleukin-1 receptor antagonist cloning, expression, functional characterization, and regulation during intestinal inflamation, *J. Biol. Chem.*, 269:6963 (1994)
*	MP	Cominelli et al., Interleukin 1(IL-1) Gene Expression, Synthesis, and Effect of Specific IL-1 Receptor Blockade in Rabbit Immune Complex Colitis, *J. Clin. Invest.*, 86:972-80 (1990)
*	MQ	Conover et al., The total synthesis of 6-demethyl-6-deoxytetracycline, *J. Am. Chem. Soc.*, 84:3222 (1962)
*	MR	Conover et al., Terramycin. XI. Tetracycline, *J. Am. Chem. Soc.*, 75:4622 (1953)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	MS	Contigiani, et al., Heterogeneity and stability characteristics of Candid 1 attenuated strain of Junin virus, *Acta Virol.*, 37(1):41-6 (1993)
*	MT	Cope et al., Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis, *J. Clin. Invest.*, 94:749-760 (1994)
*	MU	Coto, et al., Protection of guinea pigs inoculated with Tacaribe virus against lethal doses of Junin virus, *J. Infect. Dis.*, 141(3):389-93 (1980)
*	MV	Cross et al., Safety and Immunogenisity of a Polyvalent *Escherichia coli* Vaccine in Human Volunteers, *J. Infect. Dis.*, 170:834-40 (1994)
*	MW	Cryz et al., Effect of race and blood group on the immune response to bacterial polysaccharide and conjugate vaccines, *LANCET*, 2(8678-9):1533-4 (1989)
*	MX	Cryz et al., Production and Characterization of a Human Hyperimmune Intravenous Immunoglobulin against *Pseudomonas aeruginosa* and *Klebsiella* Species, *J. Infect. Dis.*, 163:1055-61 (1991)
*	MY	Current Protocols in Immunology (Ed. Coligan et al.) John Wiley & Sons, Inc., 1997
*	MZ	Cytokines Growth Factor May be an Important Immunomodulatory Agent, *Blood*, Henderson, CW (Ed.), (1999)
*	NA	Database WPI, Section Ch, Week 199618, Derwent Publications Ltd., London, GB; Class B05, AN 1996-178246, XP002146563, RU2041 711C August 20, 1995
*	NB	Dayer JM, Burger, D., Interleukin-1, tumor necrosis factor and their specific inhibitors, *Eur.Cytokine Netw.*, 5(6):563-71 (1994)
*	NC	de Guerrero et al., Pathogenesis of Attenuated Junin Virus in the Guinea Pig Model, *J. Med. Virol.*, 15(2):197-202 (1985)
*	ND	de Guerrero, et al., Early protection to Junin virus of guinea pig with an attenuated Junin virus strain, *Acta Virol.*, 29(4):334-7 (1985)
*	NE	de Bilbao et al., Acute application of an interleukin-1B-converting enzyme-specific inhibitor delays axotomy-induced motoneurone death, *Neuroreport*, 7(18):3051-4 (1996)
*	NF	Dembic et al., Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences, *Cytokine*, 2(4):231-237 (1990)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	NG	Demby et al., Early Diagnosis of Lassa Fever by Revers Transcription-PCR, *J. Clin. Microbiol.*, 32:2898-2903 (1994)
*	NH	*Dengue Haemorrhagic fever: Diagnosis, treatment, prevention and control* 2nd edition. World Health Organization, Geneva (1997)
*	NI	Despres et al., Differences Between Cell Membrane Fusion Activities of Two Dengue Type-1 Isolates Reflect Modifications of Viral Structure, *Virol.*, 196:209-19 (1993)
*	NJ	Deubel, et al., Nucleotide sequence and deduced amino acid sequence of the structural proteins of dengue type 2 virus, Jamaica genotype, *Virol.*, 155(2):365-77 (1986)
*	NK	Deubel et al., Identification of dengue sequences by genomic amplification: rapid diagnosis of dengue virus serotypes in peripheral blood, *J. Virol. Methods*, 30:41-54 (1990)
*	NL	Deubel, et al., Nucleotide sequence and deduced amino acid sequence of the nonstructural proteins of dengue type 2 virus, Jamaica genotype: comparative analysis of the full-length genome, *Virol.*, 165(1):234-44 (1988)
*	NM	Dharakul, et al., Dengue Virus-Specific Memory T Cell Responses in Human Volunteers Receiving a Live Attenuated Dengue Virus Type 2 Candidate Vaccine, *J. Infect. Dis.*, 170(1):27-33 (1994)
*	NN	Dinarello CA, Thompson RC., Blocking Il-1: interleukin 1 receptor antagonist *in vivo* and *in vitro*, *Immunol.*, 12(11):404-10 (1991)
*	NO	Dinarello CA., Interleukin-1 and Interleukin-1 Antagonism, *Blood*, 77(8):1627-52 (1991)
*	NP	Dinarello CA, Wolff SM., The Role of Interleukin-1 in Disease, *New Eng. J. Med.*, 328(2):106-13 (1993)
*	NQ	Dinarello, CA., Blocking interleukin-1 receptors, *Int. J. Clin. Lab. Res.*, 24:61-79 (1994)
*	NR	Dinarello, The biological properties of interleukin-1, *Eur. Cytokine Netw.*, 5(6):517-522 (1994)
*	NS	Dmitriev et al., Immunization with recombinant vaccinia viruses expressing strucutural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal injection, *J. Biotechnol.* 44:97-103 (1996)
*	NT	Dolle et al., Pyridazinodiazepines as a high-affinity P2-P3 peptidomimetic class of interleukin-1β-converting enzyme inhibitor, *J. Med. Chem.*, 40(13):1941-6 (1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	NU	Dolle et al., Aspartyl α-((1-Phenyl-3-(trifluoromethyl)-pyrazol-5-yl)oxy)methyl Ketones as interleukin-1β converting enzyme inhibitors. Significance of the P1 and P3 amido nitrogens for enzyme-peptide inhibitor binding, *J. Med. Chem.*, 37(23):3863-6 (1994)
*	NV	Dripps et al., Interleukin-1 (IL-1) Receptor Antagonist Binds to the 80-kDa Il-1 Receptor but Does Not Initiate IL-1 Signal Transduction, *J. Biol. Chem.*, 266(16):10331-6 (1991)
*	NW	Duangchanda, et al., Comparative nucleotide and deduced amino acid sequence of the envelope glycoprotein gene among three dengue virus type 2 strains isolated from patients with different disease severities in Maha Sarakham, northeast Thailand, *Southeast Asian J. Trop. Med. Public Health*, 25(2):243-51 (1994)
*	NX	Duggar, Aureomycin: a product of the continuing search for new antibiotics, *Ann. N.Y. Acad. Sci.*, 51:177 (1948)
*	NY	Eddy, et al., Protection of monkeys against Machupo virus by the passive administration of Bolivian haemorrhagic fever immunoglobulin (human origin), *Bull. World Health Organ.*, 52(4-6):723-7 (1975)
*	NZ	Eisenberg et al., Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist, *Nature*, 343:341-346 (1990)
*	OA	Eklund KK, Sorsa T., Tetracycline Derivative CMT-3 Inhibits Cytokine Production, Degranulation, and Proliferation in Cultured Mouse and Human Mast Cells, *Ann. N. Y. Acad. Sci.*, 878:689-91 (1999)
*	OB	Elford et al., Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1β converting enzyme, *Br. J. Pharmacol.*, 115(4):601-6 (1995)
*	OC	Elliot et al., Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis, *LANCET*, 344:1125-1127 (1994)
*	OD	Elliot et al., Randomised double-blind comparison of cheimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis, *LANCET*, 344:1105-10 (1994)
*	OE	Elliot et al., Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to Tumor Necrosis Factor α, *Arthritis & Rheumatism*, 36(12):1681-90 (1993)
*	OF	Elliot et al., Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis, *LANCET*, 244:1125-7 (1994)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	OG	Elliott et al., Improved specificity of testing methods for filovirus antibodies, *J. Virol. Methods*, 43:85-89 (1993)
*	OH	Engelmann et al., Two tumor necrosis factor-binding proteins purified from human urine evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors, *J. Biol. Chem.*, 265:1541 (1990)
*	OI	Enria et al., Current status of the treatment of Argentine hemorrhagic fever, *Med. Microbiol. Immunol.*, 175:173-176 (1986)
*	OJ	Estrov et al., Effect of interleukin-1β converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation, *Blood*, 86(12):4594-602 (1995)
*	OK	European Patent Office: Patent Abstracts of Japan. Publication Number: 04178359 Publication Date: 06/25/92; Tetracycline Derivative, JPO@Japio
*	OL	Falgout et al., Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins, *J. Virol.*, 65:2467-75 (1991)
*	OM	Falgout et al., Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a, *J. Virol.*, 63:1852-60 (1989)
*	ON	Feldmann and Slenczka Klenk, Emerging and reemerging of filoviruses, *Arch. Virol.* 11 (Suppl):77-100 (1996)
*	OO	Feldmann et al., Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages, *J. Virol.*, 70:2208-2214 (1996)
*	OP	Feldmann et al., Glycosylation and Oligomerization of the Spike Protein of Marburg Virus, *Virol.*, 182:353-356 (1991)
*	OQ	Ferretti et al., Neutralization of Endogenous IL-1 receptor Antagonist Exacerbates and Prolongs Inflammation in Rabbit Immune Colitis, *J. Clin. Invest.*, 94:449-53 (1994)
*	OR	Fidarov, et al., The cultivation and physiocochemical properties of the Josiah strain of the Lassa virus, *Vopr Virusol.*, 35(4):326-9 (1990)
*	OS	Finlay et al., Terramycin, a new antibiotic, *Science*, 111:85 (1950)
*	OT	Fischer et al., Interleukin-1 Receptor Antagonist Circulates in Experimental Inflamation and in Human Disease, *Blood*, 79(9):2196-2200 (1992)
*	OU	Fisher et al., Recombinant Human Interleukin 1 Receptor Antagonist in the Treatmnet of Patients with Sepsis Syndrome, *JAMA*, 271(23):1836-43 (1994)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	OV	Fisher et al., Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein, *New Eng. J. Med.*, 334(26):1697-1702 (1996)
*	OW	Fisher-Hoch et al., Physiological and Immunologic Disturbances Associated with Shock in a Primate Model of Lassa Fever, *J. Infect. Dis.*, 155:465-474 (1987)
*	OX	Fisher-Hoch SP., Stringent Precautions *Are not* Advisable when Caring for Patients with Viral Haemorrhagic Fevers, *Rev. Med. Virol.*, 3:7-13 (1993)
*	OY	Fisher-Hoch SP, Simpson DIH., Dangerous Pathogens, *Brit. Med. Bull.*, 41(4):391-5 (1985)
*	OZ	Fisher-Hoch et al., Pathophysiology of shock and hemorrhage in a fulminating viral infection (ebola), *J. Infect. Dis.*, 152:887-894 (1985)
*	PA	Fisher-Hoch, et al., Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene, *Proc. Natl. Acad. Sci. USA*, 86(1):317-21 (1989)
*	PB	Fletcher et al., A Synthetic Inhibitor of Interleukin-1β Converting Enzyme Prevents Endotoxin-Induced Interleukin-1β Production *In Vitro* and *In Vivo*, *J. Interferon Cytokine Res.*, 5(3):243-8 (1995)
*	PC	Forberg et al., Viral Haemorrhagic Fever in Sweden: Experiences from Management of a Case, *Scand. J. Infect. Dis,* 23:143-51 (1991)
*	PD	Frigerio et al., Cartas Al Comite De Redaccion, *Medicina(B-Aires)*, 38(5):603-4 (9178)
*	PE	Fu et al., Full-length cDNA sequence of dengue type 1 virus (Singapore strain S275/90), *Virol.*, 188(2):953-8 (1992)
*	PF	Fujiwara et al., Specific inhibition of interleukin 1β gene expression by an antisense oligonucleotide: obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells, *Cancer Res.*, 52(18):4954-9 (1992)
*	PG	Ghiringhelli et al., The glycoprotein precursor gene of the attenuated Junin virus vaccine strain (Candid #1), *Am. J. Trop. Med. Hyg.*, 56(2):216-25 (1997)
*	PH	Girardin et al., Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia, *Immunol.*, 76:20-3 (1992)
*	PI	Giri et al., Identification of Soluble Interleukin-1 Binding Protein in Cell-free Supernatants, *J. Biol. Chem.*, 265(29):17416-9 (1990)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	PJ	Granowitz et al., Interleukin-1 Receptor Antagonist Competitively Inhibits the Binding of Interleukin-1 to the Type II Interleukin-1 Receptor, *J. Biol. Chem.*, 266(22):14147-50 (1991)
*	PK	Gray et al., Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor necrosis activity, *Nature*, 312:721 (1984)
*	PL	Green, et al., Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination, *J Virol.*, 67(10):5962-7 (1993)
*	PM	Gruenberg, et al., Partial nucleotide sequence and deduced amino acid sequence of the structural proteins of dengue virus type 2, New Guinea C and PUO-218 strains, *J. Gen. Virol.*, 69(6):1391-8 (1988)
*	PN	Gu, et al., Isolation of a strain of Hantan virus from peritoneal exudate cells of a patient with hemorrhagic fever with renal syndrome, *Chin. Med. J. (Engl).*, 103(6):455-9 (1990)
*	PO	Hahn et al., Nucleotide Sequence of Dengue 2 RNA and Comparison of the Encoded Proteins with Those of Other Flaviviruses, *Virol.* 162:167-80 (1988)
*	PP	Hannum et al., Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor, *Nature*, 343:336-340 (1990)
*	PQ	Harcourt et al., Ebola Virus Selectively Inhibits Responses to Interferons, but Not to Interleukin-1β, in Endothelial Cells, *J. Virol.*, 73(4):3491-96 (1999)
*	PR	Heider et al. Genotypic characterization of mumps virus isolated in Russia (Siberia), *Res. Virol.*, 148:433-5 (1997)
*	PS	Heider et al. Comparative investigation of the long non-coding M-F genome region of wild-type and vaccine measles viruses, *Arch. Virol.*, 142:2521-8 (1997)
*	PT	Heller et al., Increased tumor necrosis factor-α levels in argentine hemorrhagic fever, *J. Infect. Dis.*, 166:1203 (1992)
*	PU	Henchal et al., Rapid identification of dengue virus isolates by using monoclonal antibodies in an indirect immunofluorescence assay, *Am. J. Trop. Med. Hyg.*, 1983, 32:164-9
*	PV	Henchal et al., Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence, *Am. J. Trop. Med. Hyg.*, 1982, 51:830-6

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	PW	Henchal et al., Sensitivity and specificity of a universal primer set for the rapid diagnosis of dengue virus infections by polymerase chain reaction and nucleic acid hybridization, *Am. J. Trop. Med. Hyg.*, 45:418-28 (1991)
*	PX	Hevey, et al., Antigenicity and Vaccine Potential of Marburg Virus Glycoprotein Expressed by Baculovirus Recombinants, *Virol.*, 239(1):206-16 (1997)
*	PY	Hiramatsu, et al., Mutational Analysis of a Neutralization Epitope on the Dengue Type 2 Virus (DEN2) Envelope Protein: Monoclonal Antibody Resistant DEN2/DEN4 Chimeras Exhibit Reduced Mouse Neurovirulence, *Virol.*, 224(2):437-45 (1996)
*	PZ	Hoke, et al., Preparation of an attenuated dengue 4 (34170 Carib) virus vaccine. II. Safety and immunogenicity in humans, *Am. J. Trop. Med. Hyg.*, 43(2):219-26 (1990)
*	QA	Holler et al., Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F), *Blood.*, 86(3):890-0 (1995)
*	QB	Horejsi, et al, The isolation of gamma globulin from blood-serum by rivanol, *Acta Med. Scand.*, 155:65 (1956)
*	QC	Houri et al., Tetracycline inhibits*Porphyromonas gingivalis*lipopolysaccharide-induced lesions*in vivo* and TNFα processing *in vitro*, *J. Periodontal Res.*, 32:183-88 (1997)
*	QD	Huggins et al., Antiviral drug therapy of Filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit ebola virus in vitro and in lethal mouse model, *J. Infect. Dis.*, 179(Supp1):S240-247 (1999)
*	QE	Huo-sheng, et al., Amplification of Dengue 2 Virus Ribonucleic Acid Sequence Using the Polymerase Chain Reaction, *Southeast Asian J. Trop. Med. Public Health*, 23(1):30-6 (1992)
*	QF	Igarashi et al., Isolation of a Singh's *Aedes albopictus* Cell Clone Sensitive to Dengue and Chikungunya Viruses, *J. Gen. Virol.*, 1978, 40:531-44
*	QG	Ignat'ev et al., The immunological indices of guinea modelling Marburg hemorrhagic fever, *Voprosy Virusologii*, 39(4):169-71 (1994)
*	QH	Ignat'ev et al., The immunity indices of animals immunized with the inactivated Marburg virus after infection with homologous virus, *Voprosy Virusologii*, 39:13-17 (1994)
*	QI	Ignat'ev et al., Induction of immune mediators in human mononuclear cells by Marburg virus, *Voprsoy Virusologii*, 43(4):169-73 (1998)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	QJ	Ignat'ev, Immune response to Filovirus infections, *Curr. Top. Microbiol. Immunol.*, 235:205-217 (1999)
*	QK	Ignat'ev et al., Immunity indices in the personnel involved in hemorrhagic virus investigation, In: Berg D. A. (ed) Proceedings of the 1996 ERDEC scientific conference on chemical and biological defense research, November 19-22, 1996, pp. 323-330 (1996)
*	QL	Ignat'ev et al., Experimental study of possible treatment of Marburg hemorrhagic fever with desferal, ribavirin, andhomologous interferon, *Voprosy Virusologii*, 41:206-209 (1996)
*	QM	Ignat'ev et al. Experimental use of vaccine in combination with immunomodulators against acute human encephalomyelitis, *Antibiotiki I Khimioterapooa*, 37(7)28-31 (1992)
*	QN	Ignat'ev et al., Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys, *J. Biotechnol.*, 44:111-118 (1996)
*	QO	Ignat'ev et al., Mechanisms of protective immune response in models of Marburg fever in monkeys, *Voprosy Virusologii*, 40:109-113 (1995)
*	QP	Ignat'ev et al., Effects of tumor necrosis factor antiserum of the course of Marburg hemorrhagic fever, *Vestnik Rossiiskoi Akademii Meditsinskikh Nauk*, (3):35-8 (1998)
*	QQ	Irie, et al., Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain), *Gene*, 75(2):197-211 (1989)
*	QR	Irie et al., Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain), *Gene*, 74:197-211 (1989)
*	QS	IUPAC-IUB commission on biochemical nomenclature symbols for amino-acid derivatives and peptides recommendations *Biochem.*, 11:1726 (1972)
*	QT	Ivanov et al., Indirect enzyme-immunoassay for laboratory diagnosis of lassa and ebola hemorrhagic fevers, *Vopr Virusol.*, 31(2):186-90 (1986)
*	QU	Jaax, et al., Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory, *LANCET*, 346(8991-8992):1669-71 (1995)
*	QV	Jahrling, et al., Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental ebola virus infections, *J. Infect. Dis.*, 179(Suppl1):S224-34 (1999)
*	QW	Jahrling, Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin, *J. Med. Virol.*, 12(2):93-102 (1983)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	QX	Jahrling, et al., Lassa virus infection of Rhesus monkeys: Pathogenesis and treatment with ribavirin, *J. Infect. Dis.*, 141(5):580-9 (1980)
*	QY	Janson et al., Production of IL-1 Receptor Antagonist by Human in Vitro-Derived Macrophages, *J. Immunol.*, 147(12):4218-23 (1991)
*	QZ	Johnson et al., Antibodies against haemorrhagic fever viruses in Kenya populations, *Trans. R. Soc. Trop. Med. Hyg.*, 77:731-733 (1983)
*	RA	Johnson et al., New mouse model for dengue virus vaccine testing, *J. Virol.*, 73(1):783-786 (1999)
*	RB	Johnson et al., Marburg, Ebola and Rift Valley fever virus antibodies in East African primates, *Trans. R. Soc. Trop. Med. Hyg.*, 76:307-310 (1982)
*	RC	Johnson, Ebola virus and hemorrhagic fever: Andromeda strain or localized pathogen?, *Ann. Intern. Med.*, 91(1):117-9 (1979)
*	RD	Johnston, Cameron. DG-DISPATCH - ISSSAT: Weight Loss A Significant Problem for Some Alzheimer's Patients, Special to DG News STOCKHOLM, SWEDEN - April 7, 2000
*	RE	Kaliberov et al. Experimental Study of the Possibility of Urgent Prevention of Bolivian Hemorrhagic Fever, *Voprosy Virusologii*, 40(5): 211-5 (1995)
*	RF	Kalinkovich et al., Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection, *Clin. Exp. Immunol.*, 89:351-55 (1992)
*	RG	Kapoor, et al., Synthesis and characterization of an infectious dengue virus type-2 RNA genome (New Guinea C strain), *Gene*, 162(2):175-80 (1995)
*	RH	Kautner, et al., Dengue virus infection: epidemiology, pathogenesis, clinical presentation, diagnosis, and prevention, *J. Pediatr.*, 131:516-524 (1997)
*	RI	Kawanaka et al., Abstract: An Evaluation of Efficacy of Minocycline as an Anti-rheumatic Drug in Patients with Active and Refractury Rheuamtoid Arthritis, 38(6):801-909 (1998)
*	RJ	Keystone et al., The Role of Tumor Necrosis Factor Antagonism in Clinical Pratice, *The J. Rheumatol.*, 26 (Suppl 57):22-8 (1999)
*	RK	Khanna, et al., Purification and amino-terminal sequence of the dengue virus-induced cytotoxic factor, *Int. J. Exp. Pathol.*, 73(1):43-9 (1992)
*	RL	Khatri et al. Experience with the use of plasmapheresisin chronic progressive multiple sclerosis: The pros, *Neurol.*, 38(7 Suppl 2):50-52 (1988)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	RM	Khatri et al. Chronic progressive multiple sclerosis: Double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs, *Neurol.*, 35:312-319 (1985).
*	RN	Khin, et al., Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in *Aedes aegypti*, *Am. J. Trop. Med. Hyg.*, 51(6):864-9 (1994)
*	RO	Kikuchi, et al., Characterization of neutralizing monoclonal antibody escape mutants of Hantaan virus 76118, *Arch. Virol.*, 143(1):73-83 (1998)
*	RP	Kiley, et al., Protection of Rhesus monkeys from Lassa Virus by immunisation with closely related arena virus, *LANCET*, 2(8145):738 (1979)
*	RQ	Kiley M.P., et al., Physcochemical Properties of Marburg Virus: Evidence for Three Distinct Virus Strains and Their Relationship to Ebola Virus, *J. Gen. Virol.*, 69:1957-1567 (1988)
*	RR	Kinney, et al., Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16681 and Its Attenuated Vaccine Derivative, Strain PDK-53[1], *Virol.*, 230(2):300-8 (1997)
*	RS	Kirkwood, et al., Non-antimicrobial and Antimicrobial Tetracy clines Inhibit IL-6 Expression in Murine Osteoblasts, *Ann. N. Y. Acad. Sci.*, 878:667-70 (1999)
*	RT	Kistler, et al., Large scale production of human plasma fractions, *Vox Sang*, 7:414 (1962)
	RU	Kloppenburg et al., Minocycline in Active Rheumatoid Arthritis, *Arthritis & Rheumatism*, 37:629-636 (1994)V
*	RV	Kloppenburg et al, The tetracycline derivative minocycline differentially affects cytokine production by moncytes and T lymphocytes, *Antimicrob. Agents. Chemother.*, 40(4):934-940 (19Y6)
*	RW	Koff, et al., Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin, *Antimicrob. Agents Chemother.*, 24(1):134-6 (1983)
*	RX	Kohno et al., A second tumor necrosis factor receptor gene product can shed a naturally occuring tumor necrosis factor inhibitor, *Proc. Natl. Acad. Sci. USA*, 87:8331-5 (1990)
*	RY	Krzesicki et al., Regulation of Expression of IL-1 Receptor Antagonist Protein in Human Synovial and Dermal Fibroblasts, *J. Immunol.*, 150(9):4008-18 (1993)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	RZ	Ksiazek et al., Enzyme Immunosorbent Assay for Ebola Virus Antigens in Tissues of Infected Primates, *J. Clin. Microbiol.*, 30(4):947-950 (1992)
*	SA	Kunitskaia, et al., The production of antibody-producing hybridomas to the Lassa virus, *Zh Mikrobiol Epidemiol Immunobiol.*, 3:67-70 (1991)
*	SB	Kuno et al., Study of Anti-Dengue NS1 Antibody by Western Blot, *J. Med. Virol.*, 1990, 32:102-8
*	SC	Kuster et al., Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation, *LANCET*, 352(9136):1271-7 (1998)
*	SD	Lam et al., Detection of Specific IgM in Dengue Infection, *Southeast Asian, J. Trop. Med. Public Health*, 18:532-8 (1987)
*	SE	Lanciotti et al., Rapid Detection and Typing of Dengue Viruses from Clinical Samples by Using Reverse Transcriptase-Polymerase Chain Reaction, *J. Clin. Microbiol.*, 1992, 30:545-51
*	SF	Langevitz et al., Treatment of Resistant Rheumatoid Arthritis with Minocycline: An Open Study, *J. Rheumatol.* 19(10):1502-1504 (1992)
*	SG	Lee et al., Minocycline in early diffuse scleroderma, *LANCET*, 352:1755-1756 (1998)
*	SH	Leblois, et al., Sequence of the dengue virus type 2 (strain PR-159) NS1 gene and comparison with its vaccine derivative, *Nucl. Acids Res.*, 21(7):1668 (1993)
*	SI	Lee, et al., Direct sequence analysis of amplified dengue virus genomic RNA from cultured cells, mosquitoes and mouse brain, *J. Virol. Methods*, 37(3):275-88 (1992)
*	SJ	LeGuenno B., et al., Isolation and partial characterisation of a new strain of Ebola virus, *LANCET*, 345:1271-127 (1995)
*	SK	Lennard, AC., Interleukin-1 Receptor Antagonist, *Critical Rev. Immunol.*, 15(1):77-105 (1995)
*	SL	Lerman, et al., Proteccion conferida por un suero hiperinmune y sus fracciones a ratas infectadas con virus Junin, *Rev. Argent. Microbiol.*, 18(1):33-5 (1986)
*	SM	Liang, et al., Bacterial Expression of Neutralizing Mouse Monoclonal Antibody Fab Fragments to Hantaan Virus, *Virol.*, 217(1):262-71 (1996)
*	SN	Libert et al., Acute phase proteins as protective factors against the toxicity of tumor necrosis factor, *Verhandelingen - Koninklijke Academie voor Geneeskunde Van Belgie* 59(6):515-23 (1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	SO	Linderholm et al., Elevated Plasma Levels of Tumor Necrosis Factor (TNF)-α, Soluble TNF Receptors, Interleukin (IL)-6, and IL-10 in Patients with Hemorrhagic Fever with Renal Syndrome, *J. Infect. Dis.*, 173:38-43 (1996)
*	SP	Linderholm et al., Increased production of nitric oxide in patients with hemorrhagic fever with renal syndrome- relation to arterial hypotension and tumor necrosis factor, *Infection*, 24:337-340 (1996)
*	SQ	Loetscher et al., Molecular Cloning and Expression of a Human 55 kd Tumor Necrosis Factor Receptor, *Cell*, 61:351-59 (1990)
*	SR	Lukiw, W.J. Neuroinflammation Roundtable, News from the Sixth International Conference on Alzheimer's Disease and Related Disorders, 18-23 July, 1998, Amsterdam. Alzheimer's Research Forum.
*	SS	Lupton et al., Inactivated vaccine for ebola virus efficacious in guinea pig model, *LANCET*, 2(8207):1294-5 (1980)
*	ST	Mackenzie, et al., Detection of complement-fixing antibody after Bolivian hemorrhagic fever, employing Machupo, Junin and Tacaribe virus antigens, *Am. J. Trop. Med. Hyg.*, 14(6):1079-84 (1965)
*	SU	Mackow, et al., The nucleotide sequence of dengue type 4 virus: analysis of genes coding for nonstructural proteins, *Virol.*, 159(2):217-28 (1987)
*	SV	Maier et al., Extension of the life-span of human endothelial cells by an interleukin-1α antisense oligomer, *Science*, 249:1570-4 (1990)
*	SW	Maiztegui et al., Efficacy of Immune Plasma in Treatment of Argentine Hemorrhagic Fever and Association Between Treatment and a Late Neurological Syndrome, *LANCET*, 1216-1217 (1979)
*	SX	Malvern, PA; Elliott et al., Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis, *LANCET*, 344:1125-1127 (1994)
*	SY	Marchette, et al., Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. I. Pre-clinical studies, *Am. J. Trop. Med. Hyg.*, 43(2):212-8 (1990)
*	SZ	Margolin et al., Substrate and Inhibitor Specificity of Interleukin-1β-converting Enzyme and Related Caspases, *J. Biol. Chem.*, 272(11):7223-8 (1997)
*	TA	Markoff et al., In vitro processing of dengue virus structural proteins: Cleavage of the pre-membrane protein, *J. Virol.*, 1989, 63:3345-52

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	TB	Martel-Pelletier *et al.* Cytokines and their Role in the Pathophysiology of Osteoarthritis, *Frontiers in Bioscience*, 4:d694-703 (1999) http://bioscience.igh.cnrs.fr/1999/v4/d/martel/fulltext.html (2/20/01)
*	TC	Martell, Boothe, The 6-deoxytetracyclines. VII. Alkylated aminotetracyclines possessing unique antibacterial activity, *J. Med. Chem.*, 10:44 (1967)
*	TD	Martinez et al., Dengue fever hemorrhagic dengue in infants with a primary infection, *Revista Cubana de Medicina Tropical*, 45(2):91-101 (1993)
*	TE	Mashima et al., Aspartate-based inhibitor of interleukin-1β-converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells +, *Biochem. Biophys. Res. Commun.*, 209(3):905-15 (1995)
*	TF	Mason, et al., Sequence of the dengue-1 virus genome in the region encoding the three structural proteins and the major nonstructural protein NS1, *Virol.*, 161(1):262-7 (1987)
*	TG	Mazzei et al., Purification and characterization of a 26-kDa competitive inhibitor of interleukin 1, *Eur. J. Immunol.*, 20:683-89 (1990)
*	TH	McColl et al., Human Neutrophils produce High Levels of the Interleukin 1 Receptor Antagonist in Response to Granulocyte/Macrophage Colony-stimulating Factor and Tumor Necrosis Factor α, *J. Exp. Med.*, 176:593-8 (1992)
*	TI	McCormick et al., A new family of antibiotics: the demethyltetracyclines, *J. Am. Chem. Soc.*, 79:4561 (1957)
*	TJ	McCormick et al., Biologic differences between strains of ebola virus from Zaire and Sudan, *J. Infect. Dis.*, 147:264-267 (1983)
*	TK	McIntyre et al., Inhibition of Interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody, *J. Exp. Med.*, 173(4):931-9 (1991)
*	TL	Milano et al., Intraperitoneal injection of tetracyclines protects mice from lethal endotoxemia downregulating inducible nitric oxide synthase in various organs and cytokine and nitrate secretion in blood, *Antimicrob. Agents. Chemother.*, 41(1):117-121 (1997)
*	TM	Mills et al., Junin Virus Activity in Rodents from Endemic and Nonendemic Loci in Central Argentina, *Am. J. Trop. Med. Hyg.*, 44(6):589-97 (1991)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	TN	Miraglia et al., Inhibition of interleukin-1 type I receptor expression in human cell lines by an antisense phosphorothioate oligodeoxynucleotide, *Int. J. Immunopharmacol.*, 18(4):227-40 (1996)
*	TO	Miyamoto, et al., An epidemiologic study on rats associated with outbreak of hemorrhagic fever with renal syndrome--comparison with antibodies for two virus strains, Hantaan virus 76-118 strain and newly isolated WKM strain, *Kansenshogaku Zasshi.*, 61(6):633-8 (1987)
*	TP	Miyamoto, et al., An epidemiologic study on HFRS after six years surveillance--comparison with antibodies for two virus strains, Hantaan virus 76-118 strain and WKM strain in members of college, *Kansenshogaku Zasshi.*, 61(6):639-44 (1987)
*	TQ	Morita et al., Rapid detection of virus genome from imported dengue fever and dengue hemorrhagic fever patients by direct polymerase chain reaction, *J. Med. Virol.*, 1994, 44:54-8
*	TR	Morita et al., Rapid Identification of Dengue Virus Serotypes by Using Polymerase Chain Reaction, *J. Clin. Microbiol.*, 29:2107-10 (1991)
*	TS	Morrison, et al., Protection of Guinea Pigs from Lassa Fever by Vaccinia Virus Recombinants Expressing the Nucleoprotein or the Envelope Glycoproteins of Lassa Virus, *Virol.*, 171(1):179-88 (1989)
*	TT	Mupapa, et al., Treatment of ebola hemorrhagic fever with blood transfusions from covalescent patients, *J. Infect. Dis.*, 179(Suppl1):S18-23 (1999)
*	TU	Murphy et al., Paltyn S.R. (ed,) Ebola and Marburg virus morphology and taxonomy, Ebola virus hemorrhagic fever, Elsevier/North-Holland, Amsterdam, pp. 61-82 (1978)
*	TV	Murphy et al., Filoviridae: Marburg and Ebola viruses, Virology (Fields and Knipe, eds.), Raven, New York, pp. 936-942 (1990)
*	TW	Muxfeldt et al., Tetracyclines. 9. Total synthesis of *dl*-terramycin, *J. Am. Chem. Soc.*, 101:689 (1979)
*	TX	Muzio, et al., Interleukin-13 Induces the Production of Interleukin-1 Receptor Antagonist (Il-1ra) and the Expression of the mRNA for the Intracellular (Keratinocyte) Form of the Il-1ra in Human Myelomonocytic Cells, *Blood*, 83(7):1738-43 (1994)
*	TY	Nabel GJ., Surviving Ebola virus infection, *Nat. Med.*, 5(4):373-4 (1999)
*	TZ	Nagahira et al., Humanization of a mouse neutralizing monoclonal antibody against tumor necrosis factor-*α* (TNF-*α*), *J. Immunol. Methods.*, 222(1-2):83-92 (1999)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	UA	Nakamura, et al., Immune spleen cell-mediated protection against fatal Hantaan virus infection in infant mice, *J. Infect. Dis.*, 151(4):691-7 (1985)
*	UB	Newton et al., Therapeutic Potential and Strategies for Inhibiting Tumor Necrosis Factor-*a*, *J. Med. Chem.*, 42(13):2295-2314 (1999)
*	UC	Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392
*	UD	O'Dell et al., Treatment of Early Rheumatoid Arthritis with Minocycline or Placebo, *Arthritis & Rheumatism*, 40(5):842-848 (1997)
*	UE	Ohlsson et al., Interleukin-1 receptor antagonist reduces mortality from endotoxin shock, *Nature*, 348(6):550-2 (1990)
*	UF	Okamoto et al., Peptide based interleukin-1β converting enzyme (ICE) inhibitors: synthesis, structure activity relationships and crystallographic study of the ICE-inhibitor complex, *Chem. Pharm. Bull. (Tokyo)*, 47(1):11-21 (1999)
*	UG	Olsson et al., Isolation and characterization of a tumor nectrosis factor binding protein from urine, *Eur. J. Haematol.*, 42:270 (1989)
*	UH	Olsson et al., A tumor necrosis factor binding protein (TNF-BP)-physiological antagonist of TNF, *Biotherapy.*, 3(2):159-65 (1991)
*	UI	Osatomi, et al., Complete nucleotide sequence of dengue type 3 virus genome RNA, *Virol.*, 176(2):643-7 (1990)
*	UJ	Osatomi, et al., Nucleotide sequence of dengue type 3 virus genomic RNA encoding viral structural proteins, *Virus Genes*, 2(1):99-108 (1988)
*	UK	Patent Abstract of Japan, vol. 016, no. 485 (C-0993), Oct. 8, 1992, JP04178359A (Kuraray Co. LTD.), June 25, 1992
*	UL	Pennica et al., *Nature*, 312:724 (1984)
*	UM	Peppel et al., A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity, *J. Exp. Med.*, 174(6):1483-9 (1991)
*	UN	Peters et al., Textbook of human virology (Belshe, ed.), Mosby Year Book, Filoviruses and management of viral hemorrhagic febers, pp. 699-712 (1991)
*	UO	Peters CJ, Jonson ED, McKee KT., Filoviruses and Management of Viral Hemmorrhagic Fevers, *Textbook of Human Virology*, Mosby year book, 699-712 (1991)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	UP	Peters CJ, LeDuc JW., An Introduction to Ebola: The Virus and the Disease, *J. Infect. Dis.*, 179(suppl 1):ix-xvi (1999)
*	UQ	Peters et al., Morphology, development, and classification of the Marburg virus, Martini and Siegert (eds) Marburg virus disease, Springer, Berlin Heidelberg, New York, pp. 68-83 (1971)
*	UR	Pethel, et al., Mutational analysis of the octapeptide sequence motif at the NS1-NS2A cleavage junction of dengue type 4 virus, *J. Virol.*, 66(12):7225-31 (1992)
*	US	Pokrovskii, et al., Inhibition of Marburg virus reproduction by glycyrrhizinic acid and its derivatives, *Dokl Akad Nauk.*, 344(5):709-11 (1995)
*	UT	Pool et al., Production of High-Potency Concentrates fo Antihemophilic Globulin in a Closed-Bag System, *New Eng. J. Med.*, 273:1443-1447 (1965)
*	UU	Porteu et al., Shedding of Tumor Necrosis Factor Receptors by Activated Human Neutrophils, *J. Exp. Med.*, 172:599-607 (1990)
*	UV	Possati et al. Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in a Kaposi's sarcoma-like murine, *Clinical & Experimental Metastasis*, 17: 575-582 (1999)
*	UW	Prehaud, et al., Recombinant Ebola virus nucleoprotein and glycoprotein (Gabon 94 strain) provide new tools for the detection of human infections, *J. Gen. Virol.*, 79(11):2565-72 (1998)
*	UX	Preugschat et al., Flavivirus enzyme-substrate interactions studied with chimeric proteinases: identification of an intragenic locus important for substrate recognition, *J. Virol.*, 1991, 65:4749-58
*	UY	Preugschat et al., Processing of Nonstructural Proteins NS4A and NS4B of Dengue 2 Virus *in Vitro* and *in Vivo*, *Virol.*, 185:689-97 (1991)
*	UZ	Preugschat et al., In vitro processing of dengue virus type 2 non structural proteins NS2A, NS2B, and NS3, *J. Virol.*, 64:4364-74 (1990)
*	VA	Price, et al., Protection against West Nile virus induced by a previous injection with dengue virus, *Am. J. Epidemiol.*, 94(6):598-607 (1971)
*	VB	Price, et al., The attenuation of the 26th mouse brain passage of New Guinea C strain of dengue 2 virus for use in the sequential immunization procedure against group B arboviruses, *Am. J. Trop. Med. Hyg.*, 22(1):92-9 (1973)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	VC	Pringle C.R., The order Mononegavirales, *Arch. Virol.*, 117:137-140 (1991)
*	VD	Pupo-Antunez, et al., Monoclonal antibodies raised to the dengue-2 virus (Cuban: A15 strain) which recognize viral structural proteins, *Hybridoma.*, 16(4):347-53 (1997)
*	VE	Puri, et al., Complete nucleotide sequence analysis of a Western Pacific dengue-1 virus strain, *Virus Genes*, 17(1):85-8 (1998)
*	VF	Putnak, et al., Immunogenic and protective response in mice immunized with a purified, inactivated, dengue-2 virus vaccine prototype made in fetal rhesus lung cells, *Am. J. Trop. Med. Hyg.*, 55(5):504-10 (1996)
*	VG	Putnak, et al., Development of a purified, inactivated, dengue-2 virus vaccine prototype in vero cells: immunogenicity and protection in mice and rhesus monkeys, *J. Infect. Dis.*, 174(6):1176-84 (1996)
*	VH	Rabinovici et al., Platelet activating factor (PAF) and tumor necrosis factor-α (TNFα) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist, *J. Pharmacol. Exp. Ther.*, 255(1):256-63 (1990)
*	VI	Race et al., Recurrent Post-Partum Haemolytic Uaemic Syndrome, *LANCET*, 1978, 1:48-9
*	VJ	Raleigh et al., McrA and McrB restriction phenotypes of some E. coli strains and implications for gene cloning, *Nucl. Acids Res.*, 16:1563-1575 (1988)
*	VK	Ramilo et al., Tumor Necrosis Factor α/Cachetin and Interleukin 1β Initiate Meningeal Inflammation, *J. Exp. Med.*, 172:497-507 (1990)
*	VL	Randolph et al., Acidotropic Amines Inhibit Proteolytic Processing of Flavivirus prM Protein, *Virol.*, 174:450-8 (1990)
*	VM	Rankin et al., The therapeutic effects of an engineered human anti-tumor necrosis factor alpha antibody (CDP751) in rheumatoid arthritis, *Br. J. Rheumatol.*, 34(4):334-342 (1995)
*	VN	Rankin et al., The Therapeutic Effects of an Engineered Human Anti-Tumor Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis, *Brit. J. Rheumatol.*, 34:334-42 (1995)
*	VO	Ray et al., Viral Inhibition of Inflammation: Cowpox Virus Encodes an Inhibitor of the Interleukin-1β Converting Enzyme, *Cell*, 69(4):597-604 (1992)
*	VP	Regna et al., The isolation and general properties of terramycin and terramycin salts, *J. Am. Chem. Soc.*, 73:4211 (1951)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	VQ	Regna, Solomons, The chemical and physical properties of terramycin, *Ann. N.Y. Acad. Sci.*, 53:221 (1950)
*	VR	Regnery et al., Virion nucleic acid of ebola virus, *J. Virol.*, 36:465-469 (1980)
*	VS	Remesar, et al., Protection against encephalitis in rats caused by a pathogenic strain of the Junin virus, using peripheral inoculation of an attenuated strain, *Rev. Argent Microbiol.*, 21(3-4):120-6 (1989)
*	VT	Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 15th Edition, 1975
*	VU	Rice et al., The togaviridae and flaviviridae (Schlesinger and Schlesinger, ed.), New York, Plenuin, 1986)
*	VV	Rice et al., Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution, *Science*, 229:726-33 (1985)
*	VW	Roehrig, et al., Monoclonal Antibody Mapping of the Envelope Glycoprotein of the Dengue 2 Virus, Jamaica, *Virol.*, 246(2):317-28 (1998)
*	VX	Salvatore et al., L-741,494, a fungal metabolite that is an inhibitor of interleukin-1β converting enzyme, *J. Nat. Prod.*, 57(6):755-60 (1994)
*	VY	Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2nd Ed.), Cold Spring Harbor Laboratory Press, 1989
*	VZ	Samoilovich, et al., Protection against a pathogenic strain of Junin virus by mucosal infection with an attenuated strain, *Am. J. Trop. Med. Hyg.*, 32(4):825-8 (1983)
*	WA	Samuel et al., Nucleotide sequence of the envelope protein gene of a Malaysian dengue-2 virus isolated from a patient with dengue haemorrhagic fever, *Nucl. Acids Res.*, 17(21):8875 (1989)
*	WB	Samuel et al., Nucleotide sequence of the envelope protein gene of a Malaysian dengue-2 virus isolated from a patient with dengue shock syndrome, *Nucl. Acids Res.*, 17(21):8888 (1989)
*	WC	Samuel et al., Nucleotide sequence of the envelope protein gene of a Malaysian dengue-2 virus isolated from a patient with dengue fever, *Nucl. Acids Res.* 17(21):8887 (1989)
*	WD	Sanchez, et al., A single nucleotide change in the E protein gene of dengue virus 2 Mexican strain affect neurovirulence in mice, *J. Gen. Virol.*, 77(10):2541-5 (1996)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	WE	Sandstom et al., Simian foamy virus infection among zoo keepers, *The Lancet* 355:551-2 (2000)
*	WF	Sarrat, et al., Diagnostic histopathologique des hepatites dues au virus lassa, *Bull Soc Pathol Exot Filiales.*, 65(5):642-50 (1972)
*	WG	Schach von Wittenau et al., 6-Deoxytetracyclines. III. Stereochemistry at C.6, *J. Am. Chem. Soc.*, 84:2645 (1962)
*	WH	Schall et al., Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor, *Cell*, 61:361-70 (1990)
*	WI	Schlesinger, et al., Protection of Mice Against Dengue 2 Virus Encephalitis by Immunization with the Dengue 2 Virus Non-structural Glycoprotein NS1, *J. Gen. Virol.*, 68(3):853-7 (1987)
*	WJ	Schlesinger et al., Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48, *J. Immunol.*, 1985, 135:2805-9
*	WK	Schmitz, et al., Use of monoclonal antibody for the detection of Lassa virus antibody and antigen in patients with Lassa fever, *Med. Microbiol. Immunol. (Berl).*, 175(2-3):181-2 (1986)
*	WL	Schreiber et al., Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNFα, but the dimer is a more potent TNF inhibitor, *J. Biol. Chem.*, 271(23):13333-41 (1996)
*	WM	Schultze, V.H.E. and G. Schwick, Uber neue Moglichkeiten intravenoser Gammaglobulin-Applikation, *Deutsche Medizinische Wochenschrift*, 87:1643-1650 (1962)
*	WN	Seah et al., Rapid, single-step RT-PCR typing of dengue viruses using five NS3 gene primers, *J. Virol. Methods*, 51:193-200 (1995)
*	WO	Seckinger et al., A Urine Inhibitor of Interleukin 1 Activity that Blocks Ligand Binding, *The J. Immunol.*, 139(5):1546-9 (1987)
*	WP	Seckinger, et al., Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor, *J. Biol. Chem.*, 264:11966 (1989)
*	WQ	Sergeev, et al., Study of the treatment-prophylactic effect of immunomodulators in experimental infections, caused by Marburg, Ebola, and Venezuelan equine encephalitis viruses, *Vopr. Virusol.*, 42(5):226-9 (1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	WR	Shapira et al., Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion, *Infect. Immun.*, 64(3):825-828 (1996)
*	WS	Sims et al., Interleukin 1 signaling occurs exclusively via the type 1 receptor, *Proc. Natl. Acad. Sci. USA*, 90:6155-9 (1993)
*	WT	Sistayanarain, et al., Primary sequence of the envelope glycoprotein of a dengue type 2 virus isolated from patient with dengue hemorrhagic fever and encepalopathy, *Southeast Asian J. Trop. Med. Public Health*, 27(2):221-7 (1996)
*	WU	Smith et al., Single-step purification of poly peptides expressed in *Escherichia coli* as fusions with glutathione S-transferase, *Gene*, 67:21-40 (1988)
*	WV	Speight et al., Gene Mapping and Positive Identification of the Non-structural Proteins NS2A, NS2B, NS3, NS4B and NS5 of the Flavivirus Kunjin and Their Cleavage Sites, *J. Gen. Virol.*, 69:23-34 (1988)
*	WW	Spinas et al., Release of Soluble Receptors for Tumor Necrosis factor (TNF) in Relation to Circulating TNF during Experimental Endotoxinemia, *J. Clin. Invest.*, 90:533-6 (1992)
*	WX	Stephan, Beseitigung der Komplementfixierung von γ-Globulin durch chemische modifizierung mit β-propiolacton, *Z. Klin. Chem. Klin. Biochemie*, 7:282 (1969)
*	WY	Stephens et al., 6-Deoxytetracyclines. IV. Preparation, C-6 chemistry, and reactions, *J. Am. Chem. Soc.*, 85:2643 (1963)
*	WZ	Stylianou et al., Interleukin 1 Induces NF-κB through Its Type I but Not Its Type II Receptor in Lymphocytes, *J. Biol. Chem.*, 267(22):15836-41 (1992)
*	XA	Suk-Yin, Chan et al., Detection and serotyping of dengue viruses by PCR: a simple, rapid method for the isolation of viral RNA from infected mosquito larvae, *Southeast Asian, J. Trop. Med. Public Health*, 25:258-61 (1994)
*	XB	Symons et al., purification and Characterization of a Novel Soluble receptor for Interleukin 1, *J. Exp. Med.*, 174:1251-1254 (1991)
*	XC	Tadano, et al., Detection of Dengue 4 Virus Core Protein in the Nucleus I. A Monoclonal Antibody to Dengue 4 Virus Reacts with the Antigen in the Nucleus and Cytoplasm, *J. Gen. Virol.*, 70 (6):1409-15 (1989)
*	XD	Tanaka et al., In vitro inhibition of binding of tumor necrosis factor (TNF)-α by monoclonal antibody to TNF receptor on Glioma cell and monocyte, *Neurol. Med. Chir. (Tokyo)*, 38(12):812-818 (1998)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	XE	Tartaglia et al., Two TNF receptors, *Immunol.*, 13:151 (1992)
*	XF	Tartaglia et al., A novel domain within the 55kd TNF receptor signals cell death, *Cell*, 74:845-853 (1993)
*	XG	Tenev et al. Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidemal growth factor-stimulated STAT1/3 activation in A431 cells, *Eur. J. Cell Biol.*, 79:261-271 (2000)
*	XH	Tesh, et al., A method for the isolation and identification of dengue viruses, using mosquito cell cultures, *Am. J. Trop. Med. Hyg.*, 1979, 28:1053-9
*	XI	The Plasma Proteins, Vol. III, 2nd Ed., Structure, Function, Genetic Control (1977) (Academic Press, Inc., N.Y.) p. 422-544
*	XJ	Tilg et al., Induction of Circulating IL-1 Receptor Antagonist by IFN Treatment, *The J. Immunol.*, 150(10):4687-92 (1993)
*	XK	Tilg et al., Interleukin-6 (IL-6) as an Anti-inflammatory Cytokine: Induction of Circulating Il-1 Receptor Antagonist and Soluble Tumor Necrosis Factor Receptor p55, *Blood*, 83(1):113-8 (1994)
*	XL	Tilley et al., Minocycline in Rheumatiod Arthritis, *Ann. Intern. Med.*, 122:81-89 (1995)
*	XM	Trappier, et al., Evaluation of the polymerase chain reaction for diagnosis of lassa virus infection, *Am. J. Trop. Med. Hyg.*, 49(2):214-21 (1993)
*	XN	Trirawatanapong, et al., Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody, *Gene*, 116(2):139-50 (1992)
*	XO	Tyle, Iontophoretic devices for drug delivery, *Pharm. Res.*, 3(6):318 (1986)
*	XP	Vallejos et al., Alteracines de ls subpoblacioes linofocita-rias en la fiebre hemorragica argentina (FHA), *Medicina (B-Aires)*, 45:407 (1985)
*	XQ	Van Ypersele de Strihou, et al., Diagnosis of Epidemic and Sporadic Interstitial Nephritis Due to Hantaan-Like Virus in Belgium, *LANCET*, 2(8365-66):1493 (1983)
*	XR	Van Vlem et al., Immunomodulating Effects of Antibiotics: Literature Review, *Infection*, 24(4):275-291 (1996)
*	XS	Van Zee et al., Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor *ain vitro* and *in vivo*, 89:4845-9 (1992)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	XT	Vannier et al., Coordinated antiinflammatory effects of interleukin 4:Interleukin 4 suppresses interleukin 1 productuion but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist, *Proc. Natl. Acad. Sci. USA*, 89:4076-80 (1992)
*	XU	Varma et al., Cell lines from larvae of *Aedes (Stegomyia) Malayensis* colless and *Aedes (S) Pseudoscutellaris* (Theobald) and their infection with some arboviruses, *Trans. R. Soc. Trop. Med. Hyg.*, 68:374-82 (1974)
*	XV	Videla, et al., Formalin inactivated junin virus: immunogenicity and protection assays, *J. Med. Virol.*, 29(3):215-20 (1989)
*	XW	Vileck et al., Tumor necrosis factor new insights into the molecular mechanisms of its multiple actions[1], *J. Biol. Chem.*, 266:7313 (1991)
*	XX	Volchkov V., et al., Emergence of Subtype Zaire Ebola Virus in Gabon[1], *Virol.*, 232:139-144 (1997)
*	XY	Wahl et al., Transforming Growth Factor-β Mediates IL-1-Dependent Induction of IL-1 Receptor Antagonist, *J. Immunol.*, 150(8):3553-60 (1993)
*	XZ	Watson et al. *Mol. Biol. Gene*, 4th Edition, 1987, The Bejacmin/Cummings Pub. co., p.224
*	YA	Weiner et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis, *Neurol.*, 39:1143-9 (1989)
*	YB	Weissenbacher, et al., Cross-protection between Tacaribe complex viruses. Presence of neutralizing antibodies against Junin virus (Argentine hemorrhagic fever) in guinea pigs infected with Tacaribe virus, *Intervirol.*, 6(1):42-9 (1975-76)
*	YC	Westaway et al., *Flaviridiae, Intervirol.*, 24:183-92 (1985)
*	YD	Wetzler et al., Altered Levels of Interleukin-1β and Interleukin-1 Receptor Antagonist in Chronic Myelogenous Leukemia: Clinical and Prognostic Correlates, *Blood*, 84(9):3142-7 (1994)
*	YE	Yadav et al., Dengue haemorrhagic fever and dengue shock syndrome: are they tumour necrosis factor-mediated disorders?, *FEMS Microbiol. Immunol.*, 89:45-50 (1991)
*	YF	Yaegashi, et al., Partial sequence analysis of cloned dengue virus type 2 genome, *Gene*, 46(2-3):257-67 (1986)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24881-301D	SERIAL NO. 10/038,557
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT FREDEKING *et al.*	
	FILING DATE January 3, 2002	GROUP 1646

** Copies of articles not enclosed.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	YG	Yahata et al., Antisense phosphorothioate oligonucleotide inhibits interleukin 1β production in the human macrophage-like cell line, U937, *Antisense Nucl. Acid Drug Dev.*, 6(1):55-61 (1996)
*	YH	Yang et al., A model to study cytokine profiles in primary and heterologously secondary Dengue-2 virus infections, *Acta Virol.*, 39(1):19-21 (1995)
*	YI	Yoo, et al., Comparison of virulence between Seoul virus strain SR-11 and Hantaan virus strain 76-118 of hantaviruses in newborn mice, *Microbiol. Immunol.*, 37(7):557-62 (1993)
*	YJ	Yoshimatsu, et al., Characterization of the nucleocapsid protein of Hantaan virus strain 76-118 using monoclonal antibodies, *J. Gen. Virol.*, 77(4):695-704 (1996)
*	YK	Zaki, et al., A novel immunohistochemical assay for the detection of ebola virus in skin: implications for diagnosis, spread, and surveillance of ebola hemorrhagic fever, *J. Infect. Dis.*, 179(Suppl1):S36-47 (1999)
*	YL	Zerek-Melen et al., Influence of interleukin 1 and antihuman interleukin 1 receptor antibody on the growth and function of the thyroid gland in rats, *Eur. J. Endocrinol.*, 131(5):531-4 (1994)
*	YM	Zulkarnain, et al., Molecular Comparison of Dengue Type 1 Monchizuki Strain Virus and Other Selected Viruses Concerning Nucleotide and Amino Acid Sequences of Genomic RNA: A Consideration of Viral Epidemiology and Variation, *Micobiol. Immunol.*, 38(7):581-5 (1994)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**

Mail date: 02/20/02